Clinical trial
A Bioequivalence Study of the Test Preparation Olanzapine Samidofen Tablets Versus the Reference Preparation Olanzapine Samidofen Tablets (LYBALVI®) in Healthy Subjects Under Fasting Conditions.
NCT07922070 is registered in ClinicalTrials.gov with The Affiliated Hospital of Qingdao University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Bioequivalence Study of the Test Preparation Olanzapine Samidofen Tablets Versus the Reference Preparation Olanzapine Samidofen Tablets (LYBALVI®) in Healthy Subjects Under Fasting Conditions.
- Lead sponsor
- The Affiliated Hospital of Qingdao University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 23, 2025
- Completion date
- November 15, 2025
- Enrollment
- 36 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
bipolar i disorder
Arms
As registered; 2 arms.
-
Group A:Test (T)-Reference (R)
-
Group B: Reference (R)-Test (T)
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Peak plasma concentration (Cmax)
-
the area under the concentration-time curve (AUC0-t )
Lead sponsor's other trials
The Affiliated Hospital of Qingdao University, most recent start first.
+143 more trials